Market research
000403.SHE Pacific Shuanglin Bio-pharmacy Co., LTD
SHE CNY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 10B
- P/E ratio
- 35.82
- Analyst target
- 25.5
- Dividend yield
- Not available
- Beta
- 0.45
Profile
Company facts
- Exchange
- SHE
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CNE000000F14
- Market cap
- 10B
- P/E ratio
- 35.82
- Analyst target
- 25.5
- Dividend yield
- Not available
- Beta
- 0.45
About
About Pacific Shuanglin Bio-pharmacy Co., LTD
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen, lyophilized intravenous immunoglobulin (pH4), hepatitis B immunoglobulin (pH4), and human prothrombin complex concentrate, as well as intravenous cytomegalovirus immunoglobulin and intravenous respiratory syncytial virus immunoglobulin. It is also involved in blood acquisition; plasma collection; consulting; trading; investment activities; and technology promotion and application services. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. was founded in 1993 and is headquartered in Taiyuan, China.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 000403.SHE discussion.
5 years, 5 months ago
Pacific Shuanglin Bio-pharmacy Co., Ltd is currently in a long term downtrend where the price is trading 13.7% below its 200 day moving average.
From a valuation standpoint, the stock is 116.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 20.8.
Pacific Shuanglin Bio-pharmacy Co., Ltd's total revenue sank by 14.6% to $235M since the same quarter in the previous year.
Its net income has increased by 23.2% to $41M since the same quarter in the previous year.
Finally, its free cash flow fell by 41.3% to $39M since the same quarter in the previous year.
Based on the above factors, Pacific Shuanglin Bio-pharmacy Co., Ltd gets an overall score of 1/5.